Arcellx

Arcellx Accounts Payable

Delisted

The Accounts Payable of Arcellx (ACLX) as of Nov 21, 2026 is 5.58 M USD. In the previous year, Accounts Payable was 2.10 M USD — a change of 166.16% (higher).

Accounts Payable

5.58 MUSD

YoY

166.16%

Last updated:

Accounts Payable of Arcellx is 2025 5.58 M USD. Accounts Payable of Arcellx was 2024 2.10 M USD. It decreases by 166.16% higher compared to the previous year.

The Arcellx Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
1.05 M USD
Jan 1, 2019
1.75 M USD
Jan 1, 2020
504,000.00 USD
Jan 1, 2021
1.33 M USD
Jan 1, 2022
9.05 M USD
Jan 1, 2023
2.62 M USD
Jan 1, 2024
2.10 M USD
Jan 1, 2025
5.58 M USD
The Arcellx Accounts Payable history
YEARAccounts PayableYoY
5.58 MUSD+166.16%
2.10 MUSD-20.01%
2.62 MUSD-71.07%
9.05 MUSD+579.14%
1.33 MUSD+164.48%
504,000.00USD-71.13%
1.75 MUSD+66.29%
1.05 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Accounts Payable of Arcellx is 5.58 M USD in 2025.

Accounts Payable of Arcellx changed from 2.10 M USD to 5.58 M USD, representing a 166.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Arcellx since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Arcellx

All Key Metrics — Arcellx